240 related articles for article (PubMed ID: 9133455)
1. Overexpression of folate binding protein in ovarian cancers.
Toffoli G; Cernigoi C; Russo A; Gallo A; Bagnoli M; Boiocchi M
Int J Cancer; 1997 Apr; 74(2):193-8. PubMed ID: 9133455
[TBL] [Abstract][Full Text] [Related]
2. Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer.
Toffoli G; Russo A; Gallo A; Cernigoi C; Miotti S; Sorio R; Tumolo S; Boiocchi M
Int J Cancer; 1998 Apr; 79(2):121-6. PubMed ID: 9583724
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor alpha as a tumor target in epithelial ovarian cancer.
Kalli KR; Oberg AL; Keeney GL; Christianson TJ; Low PS; Knutson KL; Hartmann LC
Gynecol Oncol; 2008 Mar; 108(3):619-26. PubMed ID: 18222534
[TBL] [Abstract][Full Text] [Related]
4. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
5. Folate binding protein distribution in normal tissues and biological fluids from ovarian carcinoma patients as detected by the monoclonal antibodies MOv18 and MOv19.
Mantovani LT; Miotti S; Ménard S; Canevari S; Raspagliesi F; Bottini C; Bottero F; Colnaghi MI
Eur J Cancer; 1994; 30A(3):363-9. PubMed ID: 8204360
[TBL] [Abstract][Full Text] [Related]
6. DNA ploidy, nuclear size, proliferation index and DNA-hypomethylation in ovarian cancer.
Zeimet AG; Fiegl H; Goebel G; Kopp F; Allasia C; Reimer D; Steppan I; Mueller-Holzner E; Ehrlich M; Marth C
Gynecol Oncol; 2011 Apr; 121(1):24-31. PubMed ID: 21251700
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
[TBL] [Abstract][Full Text] [Related]
8. Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia.
Pradjatmo H
Asian Pac J Cancer Prev; 2015; 16(18):8599-604. PubMed ID: 26745123
[TBL] [Abstract][Full Text] [Related]
9. Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
Skirnisdóttir I; Sorbe B; Karlsson M; Seidal T
Int J Oncol; 2001 Dec; 19(6):1295-302. PubMed ID: 11713603
[TBL] [Abstract][Full Text] [Related]
10. ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
Yan H; Qiu L; Xie X; Yang H; Liu Y; Lin X; Huang H
Oncol Rep; 2017 Mar; 37(3):1412-1418. PubMed ID: 28184931
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the 19q12 amplification including CCNE1 and URI in different epithelial ovarian cancer subtypes.
Noske A; Henricksen LA; LaFleur B; Zimmermann AK; Tubbs A; Singh S; Storz M; Fink D; Moch H
Exp Mol Pathol; 2015 Feb; 98(1):47-54. PubMed ID: 25527175
[TBL] [Abstract][Full Text] [Related]
12. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
13. Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines.
Ottone F; Miotti S; Bottini C; Bagnoli M; Perego P; Colnaghi MI; Ménard S
Br J Cancer; 1997; 76(1):77-82. PubMed ID: 9218736
[TBL] [Abstract][Full Text] [Related]
14. Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
Li Q; Liu S; Lin B; Yan L; Wang Y; Wang C; Zhang S
Int J Gynecol Cancer; 2010 Dec; 20(9):1482-9. PubMed ID: 21119363
[TBL] [Abstract][Full Text] [Related]
15. [Expression of folate receptor alpha in ovarian epithelial tumors].
Shen DH; Xie JL; Zhang YL; Wang Y
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):747-51. PubMed ID: 21215165
[TBL] [Abstract][Full Text] [Related]
16. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
Karaferic A; Jovanovic D; Jelic S
J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
[TBL] [Abstract][Full Text] [Related]
17. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
19. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
20. High-affinity folate receptor in human ovary, serous ovarian adenocarcinoma, and ascites: radioligand binding mechanism, molecular size, ionic properties, hydrophobic domain, and immunoreactivity.
Holm J; Hansen SI; Høier-Madsen M; Birn H; Helkjaer PE
Arch Biochem Biophys; 1999 Jun; 366(2):183-91. PubMed ID: 10356282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
